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Summary 
We investigated the expression and distribution  of keratinocyte growth factor (KGF)  (FGF-7) 
and  its  receptor  (KGFR.)  during  reepithelialization  of human  skin.  KGF  mR.NA  levels  in- 
creased rapidly by 8-10-fold and remained elevated for several days.  In contrast,  KGFP,. tran- 
script levels decreased early but were significantly elevated by 8-9 d. A KGF-immunoglobulin 
G  fusion protein  (KGF-HFc),  which  specifically and  sensitively  detects  the  KGFR.,  localized 
the  receptor to  differentiating  keratinocytes  of control  epidermis,  but  revealed a  striking  de- 
crease  in  receptor  protein  expression  during  the  intermediate  period  of  reepithelization. 
Suramin,  which  blocked  KGF  binding  and  stripped  already  bound  KGF  from  its  receptor, 
failed to unmask KGFR.s in tissue sections from the intermediate phase of wound  repair.  The 
absence of KGFP,. protein despite increased KGFR. transcript levels implies functional receptor 
downregulation  in  the  presence  of increased  KGF.  This  temporal  modulation  of KGF  and 
KGFR.s provides strong evidence for the functional involvement of KGF in human skin reepi- 
thelialization. 
T 
he  interactions  between  growth  factors  and  their  re- 
ceptors  play  critical  roles  in  normal  development  as 
well  as  in host  responses  to infection  and  tissue  injury.  In 
epithelial  tissues,  keratinocyte  growth  factor  (KGF) 1 (also 
designated FGF-7)  appears to be one such important medi- 
ator (1). KGF is expressed by stromal cells and acts specifi- 
cally on epithelial cells in a variety of tissues, including skin, 
lung,  and  gastrointestinal  tract,  as well  as  in  male  and  fe- 
male reproductive  organs  (2-6).  The actions of KGF have 
been most well characterized with respect to keratinocytes 
in vitro (4) and in vivo (7, 8). The growth factor is a potent 
mitogen for human  keratinocytes  in culture  and promotes 
the normal differentiation program (4). 
Evidence  that  KGF  plays  an  important  role  in  wound 
healing  derives  from recent  findings  in  animal  models.  In 
mouse  skin,  the  KGF  transcript  increased  rapidly  and  to 
high  levels  relative  to  those  of  several  other  fibroblast 
1Abbreviations used in this paper: EGF, FGF, KGF, and PDGF, epidermal, 
fibroblast, keratinocyte, and platelet-derived growth factor, respectively; 
HFc, IgG, heavy chain constant region; K1, keratin 1; KGFR, KGF re- 
ceptor. 
growth  factor (FGF)  family members analyzed in response 
to full-thickness wounding  (9). In the porcine model, topi- 
cal  application  of  KGF  to  both  split  and  full-thickness 
wounds  resulted  in  an  increased  rate  of reepithelialization 
(10). Based on these findings and the known effects of KGF 
on human keratinocytes in vitro, we sought to characterize 
the in vivo modulation  of KGF and its receptor in human 
skin  during  the  normal  wound  repair  process.  For  this 
study, we took advantage of a  new approach for KGF re- 
ceptor  immunodetection  by  means  of  a  chimeric  KGF 
ligand fused to the HFc portion of the IgG molecule  (11). 
Materials and Methods 
Tissue Preparation.  Patients  admitted  to  the  Plastic  Surgery 
Unit of the University of Rome "La Sapienza" were selected for 
the absence of any hyperproliferative skin disease or dysmetabolic 
or immunosuppressive disorder, as well as for any other pathol- 
ogy affecting the healing process. Patients ranged from 20 to 50 
yr of age  and  required  split-thickness  skin  grafts  for unrelated 
conditions.  Informed consent was obtained according to proce- 
dures approved by the Institutional Review Board of the univer- 
sity. The donor area was dressed with saline-soaked gauze. Three 
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same area.  The first was harvested at the time of surgery under 
general anesthesia, that is, on day 0, whereas the remaining biop- 
sies were taken under local anesthesia (1.5 ml carbocaine, mepiv- 
acaine, with 2% adrenaline) at varying intervals during the post- 
operative period. The biopsy donor sites were repaired with two 
5/0 nylon simple stitches. Specimens were frozen in liquid nitro- 
gen for further analysis. 
125I-KGF-binding Analysis.  KGF binding was performed us- 
ing t2SI-KGF labeled by the chloramine T  method as previously 
described (12). 
Immunohistochemistry.  Sections (5)xm) were prepared in the 
cryostat and fixed in a mixture of absolute ethanol, 1% acetone, 
1.0  mM  tetracetic acid/ethanol for 2  rain,  then  transferred  to 
100%  ethanol followed by 50%  ethanol and PBS,  pH 7.4,  and 
then placed on chromium-potassium sulfate  dodecahydrate gel- 
coated slides. After preincubation at room temperature in 5% dry 
milk, 0.1% Tween 20, and 0.05% thimerosal for 1 h, the milk was 
blotted from the slides, and the specimens were incubated either 
in the presence of the KGF-HFc chimera (11) or the control HFc 
IgG~ for 1 h  at room temperature in a humidified chamber.  In 
some experiments, tissue  sections were incubated with a mouse 
mAb  reactive  with  the  Ki67  nuclear  antigen  (Immunotech, 
Westbrook, ME) at 1:100  in 2% BSA/PBS or mouse IgG (con- 
trol). After incubation, tissues  were rinsed several times in PBS 
and further incubated in a three-step immunoperoxidase procedure. 
Immunoreactivity was  visualized using  3,3-diamino  benzidine 
tetrachloride (Pierce Chemical Co., Rockford, IL) as chromogen 
according to the manufacturer's protocol. In some experiments, 
tissue sections were incubated with 100 I~M suramin, generously 
provided by the Drug Development Branch, National Cancer In- 
stitute, as described in Results. 
Double Immunofluorescence.  For  double  immunofluorescence, 
tissue sections, prepared as described above, were incubated with 
KGF-HFc for 2 h  at 4~  in a humidified chamber, fixed in 4% 
paraformaldehyde for 30  min, and washed three times in PBS, 
followed by exposure to  FITC-conjugated secondary antibody 
(affinity-purified goat  anti-mouse  IgG)  (Cappel  Laboratories, 
Cochranville, PA). The same sections were then incubated over- 
night with polyclonal guinea pig anti-human K1  serum (kindly 
provided by Dr. Dennis Roop, Baylor Medical School, Houston, 
TX) followed by biotinylated anti-guinea pig IgG (Vector Labo- 
ratories, Inc., Budingarne, CA) and subsequently Texas red-con- 
jugated streptavidin (GIBCO BILL, Gaithersburg, MD). 
RNA  Preparation and Northern Blot Analysis.  Tissue samples 
were pulverized in the presence of liquid nitrogen and homoge- 
nized in RNAzol (TelTest). Total R_NA was precipitated with 
cold isopropanol (50% vol/vol), washed in 75% ethanol, and re- 
suspended in TE buffer (10 mM Tris-HCl, pH 7.4, and 1 mM 
EDTA).  20-p,g samples of RNA  were  electrophoresed on  1% 
formaldehyde agarose gels  and transferred to  nylon membranes 
(Nytran;  Schleicher &  SchueU,  Inc.,  Keene, NH).  To  evaluate 
the integrity of the RNA, gels were stained with ethidium bro- 
mide. After cross-linking of the RNA to the membrane, filters 
were prehybridized for 2 h at 42~  in Hybrisol (50% formamide, 
10%  dextran  sulfate,  1%  SDS,  6￿  SSC,  and  blocking agents) 
(Oncor, Inc., Gaithersburg, MD) and were hybridized for 20 h in 
the  same  solution  to  which  [32P]dCTP-labeled cDNA  probes 
were  added.  Filters were washed twice  (30  min  each time)  at 
room temperature in 2￿  SSC, 0.1% SDS, twice at 45~  in 0.1￿ 
SSC, 0.1% SDS, and exposed to x-ray film (Eastman Kodak Co., 
Rochester,  NY).  Densitometric analysis  was  performed with  a 
scanner  densitometer (Bio Rad  Laboratories, Richmond,  CA). 
Probes included cDNAs corresponding to exon 1 of the human 
KGF gene (13), a 110-bp fragment that detects the KGF receptor 
(KGFR) alternative exon  (14),  and the full coding sequence  of 
the human vimentin gene (12). 
Measurement of KGF Protein.  Tissue samples were thawed and 
homogenized with a  tissue  disrupter (Polytron; Brinkmann  In- 
struments,  Inc., Westbury, NY)  in a  solution  (2  rrd/g wet wt) 
consisting of 1.0  M  NaC1,  20  mM  Tris=HCl,  pH  7.4,  5  mM 
EDTA, 1 mM PMSF, 10 p,g/ml aprotinin, 10 p,g/ml leupeptin, 
and 10 p,g/ml pepstatin. Samples were sonicated (3 pulses of 30 s, 
power setting =  10)  (Heat Systems;  Misonix, Farmingdale, NY) 
and cleared by centrifugation at 40,000 g for 30 min at 4~  The 
protein content in the supernatants was measured, and all samples 
were adjusted to a uniform concentration before the assay. Super- 
natants were analyzed for KGF using a two-site ELISA. Briefly, 
96-well polyvinyl microtiter plates (no.  3912;  Falcon Labware, 
Oxnard, CA) were precoated overnight with 50 lxl per well of a 
KGF mAb,  1G4  (8 Ixg/ml), and subsequently blocked with 4% 
BSA.  Serial dilutions  of tissue  extracts  (protein  concentrations 
<11  Ixg/ml) were added to wells (50 Ixl per well) and incubated 
for  5  h.  Wells  were  washed  extensively with  0.05%  Tween, 
0.02%  sodium  azide in  PBS,  and  further  incubated  overnight 
with a rabbit polyclonal antibody (designated 9492)  raised against 
human  recombinant  KGF.  After  extensive  washing,  alkaline 
phosphatase-conjugated goat anti-rabbit IgG (Tago, Inc., Burlin- 
game, CA) (1:15,000 dilution) was added to the wells. After 2 h, 
the wells were  again washed  and p-nitrophenyl phosphatate  (2 
mg/ml) was added. OD was measured at 405  nm with an ELISA 
scanner (Bio Rad Laboratories). The concentration of the recom- 
binant human KGF standard (3) was based on amino acid analysis 
and extinction coefficient. 
Results 
Modulation  of KGF  and  KGFR  Transcript  Levels  during 
Human Skin Reepithelization.  In an effort to investigate the 
modulation of KGF and its receptor during normal human 
wound  repair,  we  initially measured  transcript  levels  of 
each in tissue samples at various times after split=thickness 
grafting.  The  KGF exon  I  sequence was  used as a  cDNA 
probe because this exon is present at single copy number in 
the human genome, whereas KGF exons 2 and 3 are repre- 
sented  at  multiple  copies  (13).  A  KGFR-specific cDNA 
probe was derived from the alternative exon that specifies 
KGF high affinity binding (14).  Each served as an internal 
control for  the  other in  hybridizations performed  on  the 
same tissue RNA  sarnpte. 
Fig.  1  shows  results  obtained with  two  series  of tissue 
samples  from  different  patients  during  the  course  of the 
wound  repair process.  In each  case,  KGF transcript levels 
increased substantially compared with  the  control at early 
times (1 and 3 d) and remained elevated, but to a lesser ex- 
tent,  after 7-8  d.  When  standardized relative to  vimentin 
transcript levels, the increase in KGF RNA  was as much as 
8-10-fold at early time points. These results implied a ma- 
jor  and  rapid  upregulation  in  KGF  RNA  expression  in 
wounded human  epithelium. When the same tissue RNA 
samples were  hybridized instead with  the  KGFR-specific 
probe,  we  observed decreased  KGFR  transcript  levels  at 
early time points (1  and 3  d), with a subsequent elevation 
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Figure 2.  ELISA  analysis of KGF  protein  in  wound-healing biopsies. 
KGF protein was extracted from tissue samples obtained at the time of 
surgery and  11  d  after surgery. Serial  dilutions of each sample were  as- 
sayed along with dilutions of a recombinant human KGF standard. Each 
data point represents the mean value of duplicate measurements. 
Figure  1.  Modulation of KGF and KGFR RNAs after injury. Total 
RNA was extracted from tissue samples at different periods after surgery 
and analyzed  for KGF, KGFR, and vimentin  expression  by Northern blot 
analysis. A and B represent samples  obtained from two different patients. 
Autoradiograms were quantitated by densitometry, and the induction in 
KGF and KGFR transcripts is graphically represented at the bottom of 
each panel. Filled bars correspond to KGF RNA, and stippled bars corre- 
spond to KGFR RNA. In both cases, results were standardized relative to 
vimentin transcript levels. 
of 4-5-fold above control levels after 7-8 d.  The early de- 
crease could reflect the loss of epithelial  cells  (see  below), 
which normally express the KGFR transcript (14-16). 
"Increased KGF Protein Expression in Response to Split-Thick- 
ness Wounding.  To establish whether increased KGF tran- 
script levels reflected elevated KGF protein  expression  in 
reepithelializing  skin,  we  took  advantage  of an  ELISA, 
which sensitively and specifically detects the KGF product 
(6).  As  shown  in  Fig.  2,  tissue  extracts from normal skin 
contained readily measurable KGF immunoreactivity. How- 
ever, tissue samples from the same patient taken 11  d  after 
wounding showed KGF immunoreactivity at increased lev- 
els,  corresponding to  a  sustained  two- to  threefold  eleva- 
tion in growth factor concentration.  Similar findings were 
obtained  with  other  paired  samples  from  control  versus 
reepithelializing  skin  (data  not  shown).  Thus,  increased 
KGF transcript levels correlated with elevated tissue levels 
of the growth factor. 
Immunohistochemical  Localization  of KGFRs during  Tissue 
Repair.  We  recently developed a  molecular approach to 
generate a chimeric protein encompassing the KGF coding 
sequence fused to the IgG HFc domain. This molecule can 
be  secreted  efficiently from mammalian cell  transfectants, 
and  it  combines  the  receptor-binding  properties  of the 
growth  factor and  the  convenient  detection  properties  of 
an  Ig.  Moreover,  we  demonstrated  the  specificity of this 
monoclonaMike growth factor-Ig fusion protein in the im- 
munodetection  of KGFRs by FACS  |  as well as in  tissue 
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sections  (11).  The  expression  and  distribution  of KGFRs 
were  evaluated  on  sections  of healing  wounds  using  the 
KGF-HFc chimera. 
In control skin, KGFRs were specifically localized to ke- 
ratinocytes throughout  the stratum spinosum. The pattern 
of staining was uniform around the cell surface. Little stain- 
ing was detected in either the basal layer or in the granulo- 
sum or corneum strata (Fig.  3 A).  This pattern of staining 
was consistent with our recent findings of the distribution 
of KGFRs in normal skin (11).  3 d after surgery, there was 
a marked decrease in receptor expression (Fig.  3 B), and its 
lack or greatly diminished expression persisted through the 
intermediate healing period (9 d, Fig. 3  C). During this lat- 
ter time, the suprabasal epithelium was visibly hypertrophic, 
with larger cells as well as an increased number of cell layers 
(Fig.  3  C). The striking absence of detectable KGFRs dur- 
ing this phase of the healing process resulted in a reasonably 
well-demarcated junction between the hypertrophic region 
undergoing  reepithelialization  and  noninvolved  areas, 
which expressed KGFRs (Fig.  3  D).  Of note, the  absence 
of detectable suprabasal KGFR expression occurred during 
a time which the epithelium was substantially renewed and 
expressed KGFR transcript levels four- to  fivefold higher 
than  control  skin  (Fig.  1).  At late stages in  the  process of 
reepithelialization (15 d), KGFRs remained undetectable in 
proliferating keratinocytes  of the  basal layer,  whereas  re- 
ceptor immunoreactivity had returned to the pattern of su- 
prabasat distribution observed in the control (Fig.  3 E). 
Absence of Immunodetectable  KGFRs  in Reepithelializing 
Keratinocytes Reflects Receptor Downmodulation.  The  absence 
of KGFR immunostaining during the intermediate stage of 
reepithelialization  despite  elevated KGF and  KGFR tran- 
script levels could reflect receptors occupied by increased 
levels ofligand and, thus, not available for reaction with the 
KGF-HFc probe.  Alternatively,  the lack of immunostain- 
ing could be caused by functional receptor downmodula- 
tion.  To differentiate between these  alternatives,  we took 
advantage of the knowledge that suramin, a highly anionic 
naphthalene sulfonic acid derivative (17),  can interfere with 1372  Keratinocyte Growth Factor and Its Receptor in Wound Healing Table  1.  Suramin Inhibition of Specific 12SI-KGF Binding to 
KGFR-expressing  Cells 
Treatment  Specific 12SI-KGF  bound 
12SI-KGF  10,814  -  200 
125I-KGF +  suramin  240 •  35 
wash 
125I-KGF  ) suramin  2,000 --- 50 
suramin  w~sh ) 125I_KGF  10,209 --- 220 
1251-KGF binding was performed as described in Materials and Meth- 
ods. Incubation with lzSI-KGF and/or suramin (100 I~M) was as indi- 
cated. Results represent the mean values of experiments performed in 
duplicate. 
Table 2.  Effects of Suramin on KGFR Detection in Human 
Skin Sections 
Exposure before the  Intermediate 
immunoperoxidase reaction  Control  wound repair 
KGF-HFc  w~h )  Positive  Negative 
KGF-HFc +  suramin  w~sh )  Negative  Negative 
KGF-HFc  w~ )  suramin  wash )  Negative  Negative 
suramin  wash ) KGF-HFc  Positive  Negative 
KGFR immunostaining was performed as described in Materials and 
Methods, according to the protocol  as indicated for incubation with 
KGF-HFc and/or suramin (100 IxM). 
binding by certain growth factors (18).  Table  1 shows that 
suramin dramatically inhibited specific 12SI-KGF binding to 
its  receptor  (Table  1).  Moreover,  suramin  treatment  was 
capable  of efficiently  removing  already  bound  12SI-KGF 
from cells  (Table  1).  Of note,  the  effects of suramin were 
completely  reversible.  Thus,  washing  of suramin-treated 
cells before ligand exposure was associated with 12SI-KGF- 
specific binding levels comparable to that of untreated cells 
(Table  1). 
We next investigated the effects of suramin exposure on 
KGFR  detectability  in  tissue  sections  of control  skin.  As 
summarized  in  Table  2,  the  KGF-HFc  demonstrated  the 
expected  staining  of the  stratum  spinosum.  Simultaneous 
exposure  to  suramin  effectively blocked KGF-HFc  bind- 
ing, but immunostaining was readily observed when tissue 
sections were first  exposed  to suramin  and washed before 
immunostaining  with  KGF-HFc  (Table  2).  These  results 
established  that suramin  treatment  did not irreversibly im- 
pair the ability of the KGF-HFc to detect KGFRs.  To de- 
termine  whether  suramin  was  also  capable  of stripping 
ligand already bound to receptors,  tissue sections were in- 
cubated  with  KGF-HFc,  washed,  and  then  exposed  to 
suramin.  After a  second series  of washes,  immunoperoxi- 
dase  staining  was  performed.  Under  these  conditions,  no 
KGFR immunostaining was observed (Table  2),  establish- 
ing that  suramin  was  also  capable  of removing KGF-HFc 
already bound to KGFRs in the tissue section. In tissue sec- 
tions from the intermediate stage of wound reepethelializa- 
tion, which lacked detectable  KGFR immunostaining,  re- 
ceptor  immunoreactivity  was  not  unmasked  by  previous 
exposure  to  suramin  (Table  2).  All  of these  results  pro- 
vide  strong evidence  that  the  absence  of immunoreactive 
KGFRs  during  a  time  in  wound  repair  when  KGF  and 
KGF1K  transcript  levels  were  both  markedly  elevated  re- 
flects functional receptor downmodulation. 
KGFR  Downregulation  Is  Associated  with  a  Differentiating 
Keratinocyte  Population.  The  striking  lack  of correspon- 
dence between  KGF1K RNA  and protein  expression  dur- 
ing the intermediate phase of reepithelialization was consis- 
tent with the emergence during this period of a suprabasal 
population whose phenotype resembled that of the KGFR- 
negative  progenitor localized to  the  basal layer of normal 
skin. Alternatively, the cells might represent differentiating 
keratinocytes whose KGFRs were downregulated because 
of increased levels  of KGF.  In the  normal  epidermis,  the 
expression  of human keratin  1  (K1)  is associated with the 
commitment  of basal  cells  to  terminal  differentiation  and 
the loss of proliferative  capacity (19,  20).  In an attempt to 
distinguish  between  these  possibilities,  we  compared  the 
localization  of  KGF1Ks  with  the  distribution  of  K1  in 
wound-healing samples. 
In normal  skin,  we  observed  colocalization  of KGFRs 
and K1 in cells of the stratum spinosum (Fig. 4, A  and B). 
Whereas KGF1Ks were localized to the plasma membrane, 
K1  was present  in the  cytoplasm. At 3  d,  the  few kerati- 
nocytes observed in tissue sections lacked both KGFR and 
K1 protein expression, consistent with a progenitor pheno- 
type  (data not shown).  By 9  d,  however,  the pattern  was 
very different  (Fig.  4,  C  and  D).  Despite  the  absence  of 
KGFRs, the same suprabasal cells  were invariably K1 posi- 
tive  compared  with  basal  cells  in  the  same  sections  that 
lacked detectable  K1  expression.  By day 15, wounds were 
reepithelialized  (Fig.  4,  E  and  b-), and  the  newly formed 
epidermis exhibited a normal pattern of differentiation mark- 
ers,  with  colocalization of KGF1Ks  and  K1  in  cells  of the 
stratum spinosum (Fig.  1,  E  and b].  Ki67 immunostaining 
confirmed  that  suprabasal  cells  during  the  intermediate 
wound-healing  phase  were  nondividing.  This  marker  of 
cells  undergoing DNA synthesis  (21)  was localized to basal 
cells  in  control skin  and was more prominently  observed 
Figure 3.  Immunoperoxidase  localization of KGF1Ks within skin samples during reepithelializaton. Immunostaining  was performed as described in Ma- 
terials and Methods. (A) In normal skin, KGF1K staining localized to the cell surface throughout the stratum spinosum. (B) At 3 d, no detectable staining 
of  KGFRs is observed in the wound area. (C) At 9 d, during the intermediate period of  healing, the reepithehalizing hyperthrophic epidermis appears vir- 
tually unstained. (D) On the same day, epithelial margins adjacent to a hypertrophic region undergoing reepithelialization show marked staining for KG- 
F1Ks. (E) At 15 d, the epidermis is totally reepithelialized, showing a pattern of  staining comparable to normal skin; immunostaining  with the HFc control 
was negative under the same conditions (data not shown). A and C-E, X400; B, X800. 
1373  Marchese et al. Figure 4.  Localization of KGFR and K1 on normal and wounded skin. Double immunofluorescence  staining with FITC for KGFRs, using chimeric 
HGF-HFc (/t,  C, and E), and TRITC for K1, using anti-human K1 polyclonal antibody  (B, D, and F), on normal and wounded skin sections. Immun- 
ostaining was performed as described in Materials and Methods.  Colocalization  of KGFRs in the plasma membranes and K1 in the cytoplasm are shown 
in the cells of the stratum spinosum of normal skin. In the same section, the basal layer remains unlabeled for both KGFR and K1  (A and B). At 9 d of 
healing, the cells lack detectable expression of KGFRs, whereas in the same suprabasal cells, the signal for K1 is positive and irregularly distributed  (C and 
D). At 15 d, tissue samples again show reactivity in cells of the suprabasal layer for both KGFRs and K1 (E and F). ￿ 
in  cells of the basal layer of keratinocytes  during the inter- 
mediate  wound-healing  phase.  However,  Ki67-positive 
cells  were  not  observed  in  hypertropic  suprabasal  cells  of 
the same tissue  (data  not shown).  Thus,  the absence  of de- 
tectable  KGFRs  in  suprabasal  Kl-expressing  cells  during 
the  intermediate  period  reflects KGFR  downregulation  in 
the  nondividing,  differentiating  keratinocyte  population. 
As  such,  these  results  imply  that  KGF  plays  a  functional 
role in wound  repair and may help to regulate the commit- 
ment to keratinocyte differentiation. 
1374  Keratinocyte Growth Factor and Its Receptor in Wound Healing Discussion 
In  these  studies,  we  observed  increased  expression  of 
KGF,  an  epithelial  cell-specific paracrine  growth  factor, 
during  reepithelialization  of normal  human  skin.  KGF 
transcript levels increased as much as 8-10-fold during the 
early postwound periods  accompanied by an  elevation of 
2-3-fold in growth factor protein expression in the same 
tissues. Elevated KGF transcript levels of even higher mag- 
nitude  have  been  recently reported in  a  mouse wound- 
healing model (9). Studies in tissue culture have shown that 
a  number  of growth  factors,  including  platelet-derived 
growth factor (PDGF) and TGF-ct, increase KGF transcript 
levels  in  human  fibroblasts  (22).  Moreover,  the  pro- 
inflammatory cytokine, IL-lot, was  shown  to  induce  the 
KGF transcript by a mechanism involving increased gene 
transcription (22).  Because a number of these factors may 
be elevated during wound repair, any or all may be impli- 
cated in the in vivo activation ofKGF gene expression. 
There was  also  striking  modulation  of KGFIL expres- 
sion.  KGFP,  transcript  levels  increased  several-fold over 
basal levels in control skin during the intermediate period 
of wound  repair.  Whereas  control  epithelium  expressed 
readily detectable receptor protein throughout the stratum 
spinosum, KGFP, protein expression was low or absent in 
the hypertrophic suprabasal  keratinocytes of renewing skin. 
The lack  of detectable receptors during  the  intermediate 
phase of wound repair might reflect competition for recep- 
tor binding by overexpressed KGF. However, we showed 
that suramin, which effectively stripped bound ligand from 
KGFRs,  was  unable  to  unmask  cell  surface  KGFP,  s  in 
reepithelializing skin.  It  is  well  established  that  acute  or 
chronic exposure to growth factors such as epidermal growth 
factor (EGF), PDGF, or FGF cause receptor activation and 
their internalization, which leads to a marked reduction in 
the number of cell surface receptors (23).  Thus, we  con- 
clude that the loss of immunodetectable KGF1Ls in supra- 
basal  keratinocytes  of reepithelizing  human  skin,  under 
conditions in which transcript levels of both KGF and the 
KGFP, were increased, reflects activation and downregula- 
tion of the KGFP,. As such,  KGF must  contribute func- 
tionally to the reepithelialization process. 
Previous studies in tissue culture have shown that TGF-0t 
or EGF acting through the EGF receptor can block Ca  2+- 
induced  terminal  differentiation of human  keratinocytes, 
whereas KGF allows this differentiation process to proceed 
(4).  Moreover, in a porcine wound repair model, exoge- 
nous  KGF  increased fete ridge  formation,  as  well as  the 
thickness  of the  superbasal  layers  of reepithelialized skin 
(10).  In the rabbit ear wound repair model, KGF exposure 
was associated with accelerated epithelialization with evi- 
dence of specific stimulation of the proliferation and differ- 
entiation of progenitors within the hair follicles and seba- 
ceous glands,  in addition to the epidermis (24).  Our results 
with normal human skin showed that suprabasal  cells of re- 
generating  epithelium  expressed K1,  a  marker  of kerati- 
nocyte differentiation, and lacked evidence of proliferation, 
supporting  the  concept  that  KGF  functions  in  human 
wound repair in vivo to promote the keratinocyte differen- 
tiation process. KGFIL protein expression was also low or 
undetectable in the basal  keratinocytes during wound re- 
pair,  where  the  index of cell proliferation was  increased 
several-fold over that of basal  cells  of control skin.  Thus, 
KGF may also play a role in the functional downmodula- 
tion ofKGFP,  s in progenitor cells, which have the capacity 
to proliferate as well as differentiate. 
Independent evidence for the effects of KGF in kerati- 
nocyte proliferation/differentiation in vivo derives from re- 
cent studies  in  transgenic  mice  in which  KGF  (25)  or a 
dominant-negative KGF receptor (26) was targeted by the 
K14 promoter for overexpression in undifferentiated basal 
keratinocytes. The former was associated with hyperthick- 
ening of the epidermis (25),  whereas the latter was associ- 
ated with epidermal atrophy, a reduced steady-state prolif- 
eration rate of the basal  epithelial cell layer, and reduced 
epithelialization after wounding (26). Wound healing in- 
volves  a  complex  series  of interactions  involving  many 
different cell types and  the  release of growth factors and 
cytokines (27-30). In this study, the elevation in KGF pro- 
duction in association with the  downregulation of its  re- 
ceptor in keratinocytes during normal wound healing sug- 
gests  a key role for this  growth factor in maintaining the 
balance between proliferation and differentiation in the hu- 
man regenerating epithelium. 
We thank Kim Meyers and Robert Dayton for their excellent technical assistance. 
The work at the University of Rome was partially supported by grants from the Associazione Italiana per la 
Ricerca sul Cancro  and from the  Consiglio Nationale delle R.icerche Progetto  Finalizzato Applicazioni 
Cliniche della P,.icerca  Oncologic~. 
Address correspondence to Stuart A. Aaronson, The Derald H. Ikuttenberg Cancer Center, Mount Sinai 
School of  Medicine, 1 Gustave L. Levy Place, Box 1130, New York, NY 10029. 
Received  for publication 12 September 1994 and in revised  form 21 June 1995. 
1375  Marchese  et al. References 
1.  Rubin, J.S., H. Osada, P.W. Finch, W.J. Taylor, S. Rudikoff, 
and S.A. Aaronson. 1989. Purification and characterization of 
a newly identified growth factor specific for epithelial cells. 
Proc. Natl. Acad.  Sci.  USA.  86:802-806. 
2.  Finch, P.W., J.S. Rubin, T. Miki, D. Ron, and S.A. Aaron- 
son. 1989. Human KGFR is FGF-related with properties of a 
paracrine  effector  of epithelial cell  growth.  Science (Wash. 
DC). 245:752-755. 
3.  Ron,  D., D.P. Bottaro, P.W. Finch, D. Morris, J.S. Rubin, 
and  S.A. Aaronson.  1993.  Expression of biologically active 
recombinant keratinocyte growth factor. Ji  Biol.  Chem.  268: 
2984-2988. 
4.  Marchese, C., J.S. Rubin, D. Ron, A. Faggioni, M.R.  Tor- 
risi, A. Messina, L.  Frati, and S.A. Aaronson.  1990.  Human 
keratinocyte growth factor activity on proliferation and dif- 
ferentiation of human keratinocytes: differentiation response 
distinguishes KGF  from  EGF  family. J.  Cell.  Physiol.  144: 
326-332. 
5.  Alarid, E.T., J.S.  Rubin,  P.  Young,  M.  Chedid,  D.  Ron, 
S.A. Aaronson, and G.R. Cunha.  1994. Keratinocyte growth 
factor functions in epithelial induction during seminal vesicle 
development. Pro& Natl. Acad.  Sci.  USA.  91:1074-1078. 
6.  Koji, T., M. Chedid, J.S. Rubin, O.D. Slaiden, K.G. Csaky, 
S.A.  Aaronson,  and  R.M.  Brenner.  1994.  Progesterone- 
dependent expression of keratinocyte growth factor mRNA 
in  stromal  cells  of the  primate  endometrium:  keratinocyte 
growth factor as a progestomedin.J. Cell Biol.  125: 393-401. 
7.  Guo, L., Q.O. Yu, and E. Fuchs. 1993.  Targetting expresion 
of keratinocyte growth factor to keratinocytes elicits striking 
changes in epithelial differentiation in transgenic mice. EMBO 
(Eur. Mol,  Biol.  Organ.) J.  12:973-986. 
8.  Ulich,  T.R.,  E.S.  Yi,  R.  Cardiff,  S.  Yin,  N.  Bikhazi,  R. 
Blitz,  C.F.  Morris,  and  G.F.  Pierce.  1994.  Keratinocyte 
growth factor is a growth factor for mammary epithelium in 
vivo. Am.J.  Pathol.  144:862-868. 
9.  Werner, S., K.G. Peters, M.T. Longake, F. Fuller-Pace, M.J. 
Banda, and L.T. Williams. 1992.  Large induction of kerati- 
nocyte growth factor expression in the dermis during wound 
healing. Pro& Natl. Acad.  Sci.  USA.  89:6896-6900. 
10. Staiano-Coico, L., G.J.  Knleger, J.S. Rubin, S. D'limi, V.P. 
Vallat, L.  Valentino, T.  Fahey III, A. Hawes,  G. Kingston, 
M.R. Madden, et al. 1993.  Human keratinocyte growth fac- 
tor effects in a porcine model of epidermal wound healing. J. 
Exp. Med.  178:865-878. 
ll. LaRochelle, W.J., O.R.  Dirsch, P.W. Finch, H.-G. Cheon, 
M. May, C. Marchese, J.H. Pierce, and S.A. Aaronson. 1995. 
Specific  receptor  detection  by  a  functional  keratinocyte 
growth  factor-immunoglobulin chimera. J.  Cell  Biol.  129: 
357-366. 
12. Lilienbaum, A., M.  Duc Dodon,  C. Alexandre, L. Gazzolo, 
and D. Paulin.  1990.  Effect of human  T-cell leukemia virus 
type I tax protein on activation of the human vimentin gene. 
J.  Virol. 64:256-263. 
13. Kelly,  M.J.,  M.  Pech,  H.N.  Seuanez,  J.S.  Rubin,  S.J. 
O'Brien, and S.A. Aaronson. 1992. Emergence of the kerati- 
nocyte growth factor multigene family during the great ape 
radiation. Proc. Natl. Acad.  Sci.  USA.  89:9287-9291. 
14. Miki,  T.,  D.P.  Bottaro,  T.P.  Fleming,  C.L.  Smith,  W.H. 
Burges, A.M.-L. Chan, and S.A. Aaronson.  1992.  Determi- 
nation  of ligand binding specificity by  alternative splicing: 
two  distinct  growth  factor  receptors  encoded  by  a  single 
gene. Proc. Natl. Acad.  Sci.  USA.  89:246-250. 
15. Bottaro, D.P., J.S.  Rubin,  D. Ron,  P.W.  Finch, C.  Florio, 
and  S.A. Aaronson.  1990.  Characterization of the  receptor 
for  keratinocyte growth  factor. J.  Biol.  Chem.  265:12767- 
12770. 
16. Miki, T.,  T.P.  Fleming, D.P. Bottaro, J.S. Rubin,  D.  Ron, 
and S.A. Aaronson.  1991.  Expression cDNA cloning of the 
KGF receptor by creation of a transforming autocrine loop. 
Science (Wash. DC). 251:72-75. 
17. Ehrlich,  P.,  and K.  Shiga.  1904.  Farbentherapeutishce ver- 
suche bei trypanosomenerkrankung. Berl.  Klin.  Wchnschr. 41: 
329. 
18. Fleming, T.P.,  T.  Matsui,  C.J.  Molloy, K.C.  Robbins, and 
S.A. Aaronson.  1989.  Autocrine mechanism for v-sis trans- 
formation requires cell surface  localization of internally acti- 
vated growth factor receptors. Proc. Natl. Acad.  Sci.  USA.  86: 
8063-8067. 
19. Kartasova, T., D.R. Roop, and S.H. Yuspa. 1992.  Relation- 
ship between  the  expression of differentiation specific ker- 
atins 1 and 10 and cell proliferation in epidermal tumors. MoL 
Carcinog. 6:18-25. 
20.  Fuchs, E., and H. Green.  1980.  Changes in keratin gene ex- 
pression during terminal differentiation of the keratinocyte. 
Cell.  19:1033-1042. 
21.  Gerdes, J., U. Schwab, H. Lemke, and H. Stein.  1983.  Pro- 
duction of a mouse monoclonal antibody reactive with a hu- 
man nuclear antigen associated with cell proliferation. Int. J. 
Cancer. 31 : 13-20. 
22.  Chedid,  M., J.S.  Rubin,  K.G.  Csaky,  and  S.A.  Aaronson, 
1994. Regulation ofkeratinocyte growth factor gene expres- 
sion by interleukin 1._/. Biol.  Chem. 269:10753-10757. 
23.  Ullrich, A., and J. Schlessinger. 1990.  Signal transduction by 
receptors with tyrosine kinase activity. Cell.  61:203-212. 
24.  Pierce, G.F., D. Yanagihara, K. Klopchin, D.M. Danilenko, 
E. Hsu, W.C. Kenney, and C.F. Morris. 1994. Stimulation of 
all  epithelial elements  during  skin  regeneration  by  kerati- 
nocyte growth factor.]. Exp. Med.  179:831-840. 
25.  Guo, L., Q.O. Yu, and E. Fuchs. 1993. Targetting expression 
of keratinocyte growth factor to keratinocytes elicits striking 
changes in epithelial differentiation in transgenic mice. EMBO 
(Eur.  Mot. Biol.  Organ.).].  12:973-986. 
26.  Werner,  S.,  H.  Smola, X.  Liao, M.T.  Longaker,  T.  Krieg, 
P.H.  Hot~chneider, and L.T.  Williams. 1994.  The function 
of KGF in morphogenesis of epithelium and reepithelializa- 
tion of wounds. Science (Wash. DC). 266:819-822. 
27. Lynch,  S.E.,  R.B.  Colvin,  and  H.N.  Antoniades.  1989. 
Growth factors in wound healing.J. Clin, Invest.  84:640-646. 
28.  Pierce, G.F. 1993.  Growth factors in soft tissue repair and re- 
generation. FASEB (Fed. Am.  Soc. Exp.  Biol.)J. 7:A193. 
29.  Gartner, M.H.,J.D. Benson, and M.D. Caldwell. 1992.  Insu- 
lin-like growth  factors  I  and  II  expression  in  the  healing 
wound.J.  Surg. Res. 52:389-394. 
30.  Mariowsky, M., K. Breuing, P.Y. Liu, E. Erikson, S. Higash- 
iyama, P. Farber, J. Abraham, and M.  Klagsbum. 1993.  Ap- 
pearance  of  heparin  binding  EGF-like  growth  factor  in 
wound  fluid as  a  response  to  injury.  Proc. Natl.  Acad.  Sci. 
USA.  90:3889-3893. 
1376  Keratinocyte Growth Factor and Its Receptor in Wound Healing 